ClearPoint Neuro (NASDAQ:CLPT) Announces Quarterly Earnings Results, Misses Estimates By $0.05 EPS

ClearPoint Neuro (NASDAQ:CLPT) issued its quarterly earnings results on Wednesday. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05), Zacks reports. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. The business had revenue of $7.77 million during the quarter, compared to the consensus estimate of $8.23 million. ClearPoint Neuro updated its FY 2025 guidance to EPS.

ClearPoint Neuro Stock Up 2.8 %

Shares of ClearPoint Neuro stock traded up $0.40 during trading on Friday, hitting $14.61. The stock had a trading volume of 181,599 shares, compared to its average volume of 225,384. ClearPoint Neuro has a 1 year low of $5.11 and a 1 year high of $19.22. The stock has a 50 day simple moving average of $16.66 and a 200 day simple moving average of $13.81. The company has a market capitalization of $402.88 million, a PE ratio of -21.17 and a beta of 1.03.

Analyst Upgrades and Downgrades

Several research firms recently commented on CLPT. Lake Street Capital increased their target price on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, January 21st. B. Riley increased their price objective on ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.